Cogent Biosciences, Inc. Shareholders' Equity
Cogent Biosciences, Inc. (COGT) had Shareholders' Equity of $532.39 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $532.39M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $607.69M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $636.37M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $302.46M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $532.39M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $607.69M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $636.37M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $302.46M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $155.04M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $219.00M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $256.29M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $314.66M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $373.22M 10-Q · filed 2025-11-07 |
| 2024-03-31 | $422.33M 10-Q · filed 2025-11-07 |
| 2023-12-31 | $257.80M 10-K · filed 2026-02-17 |
| 2023-09-30 | $302.90M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $348.43M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $223.56M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $255.74M 10-K · filed 2026-02-17 |
| 2022-09-30 | $289.94M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $319.38M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $187.86M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $214.18M 10-K · filed 2025-02-25 |
| 2021-09-30 | $197.24M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $212.80M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $226.76M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $234.67M 10-K · filed 2024-02-26 |
| 2020-09-30 | -$22.17M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $19.24M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $25.70M 10-Q · filed 2021-11-10 |
| 2019-12-31 | $31.76M 10-K · filed 2022-03-15 |
| 2019-09-30 | $28.62M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $39.76M 10-Q · filed 2020-11-09 |
| 2019-03-31 | $49.29M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $60.23M 10-K · filed 2021-03-16 |
| 2018-09-30 | $67.53M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $76.67M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$61.27M 10-Q · filed 2019-11-12 |
| 2017-12-31 | -$48.85M 10-K · filed 2020-03-26 |
| 2016-12-31 | -$24.70M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |